LXRX - NASDAQ
Lexicon Pharmaceuticals, Inc.
$1.94
+2.4%Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
At a Glance
Live Snapshotlxrx
Additional Paid-In Capital
Last Annual Value
2.13B
3-Year CAGR
8%
5-Year CAGR
6%
10-Year CAGR
4%
Lexicon Pharmaceuticals, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | 2.13B | 4.6% | 5.8% | 4.2% | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 804.39M | 8.4% | 11.3% | N/A | |
 Ocugen, Inc. NASDAQ:OCGN | 392.76M | 6.6% | 11.7% | 7.2% | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 0.00 | N/A | N/A | N/A | |
 4D Molecular Therapeutics, Inc. NASDAQ:FDMT | 1.22B | 19.1% | 18.3% | N/A | |
 Fulcrum Therapeutics, Inc. NASDAQ:FULC | 0.00 | N/A | N/A | N/A | |
 Compass Therapeutics, Inc. NASDAQ:CMPX | 0.00 | N/A | N/A | N/A | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 1.32B | 1.2% | 7.2% | N/A | |
 Omeros Corporation NASDAQ:OMER | 791.75M | 2.8% | 2.3% | 6.2% |
Lexicon Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your LXRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.